Thu, Mar 27, 11:18 AM (34 days ago)
### Summary of AIM ImmunoTech Inc. (AIM) **Financial Performance:** - **Revenue:** $170,000 (2024) vs. $202,000 (2023) - **Net Loss:** $17,320,000 (2024) vs. $28,962,000 (2023) - **Operating Expenses:** $19,942,000 (2024) vs. $32,118,000 (2023) - **Earnings per Share:** $(0.31) (2024) vs. $(0.60) (2023) **Strategic Overview:** - **Products:** Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). - **Focus Areas:** Pancreatic cancer, ME/CFS, Post-COVID conditions, antiviral research, and vaccine adjuvant development. - **Clinical Trials:** Ongoing trials for pancreatic cancer, ME/CFS, and Post-COVID conditions. - **Partnerships:** Collaborations with Amarex Clinical Research, Erasmus Medical Center, and AstraZeneca. **Future Outlook:** - **Market Position:** AIM aims to leverage its proprietary technologies and strategic partnerships to advance its products through clinical trials and regulatory approvals. - **Risk Factors:** Financial instability, regulatory hurdles, and competition from larger pharmaceutical companies. - **Financial Condition:** Significant net losses and a working capital deficit, raising substantial doubt about the ability to continue as a going concern. **Market Position Changes:** - **Stock Performance:** The closing price of the common stock on March 24, 2025, was $0.14 per share. - **Delisting Risk:** The company received an official notice of noncompliance with the NYSE American’s continued listing requirements and must regain compliance by June 11, 2026. **Other Notable Points:** - **Patents and Exclusivity:** AIM holds 59 patents worldwide with 71 additional pending patent applications. - **Orphan Drug Designation:** Received for Ampligen and Alferon N Injection for various indications. - **Manufacturing:** Collaborations with Jubilant HollisterStier and Sterling for the production of Ampligen and its intermediates.